BioCentury
ARTICLE | Clinical News

Arverapamil: Development discontinued

May 18, 2009 7:00 AM UTC

AGI said it would discontinue development of Rezular for IBS-D after top-line data from the double-blind, international Phase III ARDIS-1 trial in 711 patients showed that Rezular missed the primary e...